Jupiter Life Line Hospitals’ IPO to open on Sept. 6
Sets price band at ?695 to ?735 per Equity Share
Sets price band at ?695 to ?735 per Equity Share
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
The approval bolsters the company's Mycophenolate Mofetil portfolio
Propranolol LA is a generic equivalent of Inderal LA
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
The 100 surgeries conducted using robotic technology span various intricate procedures in the fields of Urology, Liver Transplantation, GI surgery, Cardiac surgeries and Gynaecology
Subscribe To Our Newsletter & Stay Updated